Antibodies targeting xcl1 and methods of using the same
AssigneeEli Lilly and Company
InventorsStephanie Lynn BEASLEY, Patrick Francis GREALISH, Jingxing LI, Chad D. PAAVOLA, Joshua Dade POORBAUGH, Matthew Alan RENSCHLER, Ying TANG, Mark Andrew WORTINGER
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds and methods targeting human lymphotactins, including therapeutic antibodies, pharmaceutical compositions and methods of use thereof, useful in the field of immune-mediated diseases including ulcerative colitis, vitiligo, multiple sclerosis, alopecia areata, psoriasis, type 1 diabetes, and asthma.
Claims26
An antibody that binds human XCL1 comprising a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein the HCVR comprises complementarity determining regions (CDRs) HCDR1, HCDR2, and HCDR3 and the LCVR comprises CDRs LCDR1, LCDR2, and LCDR3, wherein,
- the HCDR1 comprises SEQ ID NO:
- 10,
- the HCDR2 comprises SEQ ID NO:
- 11,
- the HCDR3 comprises SEQ ID NO:
- 12, wherein Z is selected from Q and E,
- the LCDR1 comprises SEQ ID NO:
- 5, wherein X is selected from S and D,
- the LCDR2 comprises SEQ ID NO:
- 8, and
- the LCDR3 comprises SEQ ID NO:
- 9.
An antibody that binds human XCL1, comprising a heavy chain (HC) having at least 95% sequence identity to SEQ ID NO:
- 19 and SEQ ID NO:
- 20, and a light chain (LC) having at least 95% sequence identity to SEQ ID NO:
- 21 and SEQ ID NO:
- 22.
A nucleic acid comprising a sequence encoding SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 25, or SEQ ID NO:
- 26.
A vector comprising a first nucleic acid sequence encoding SEQ ID NO:
- 23 or SEQ ID NO:
- 25 and a second nucleic acid sequence encoding SEQ ID NO:
- 24 or SEQ ID NO:
- 26.
Dependencies are inferred from the claim text.